Stocks
LENZ Therapeutics, Inc.LENZ
NASDAQHealthcareBiotechnology$3.16
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing LNZ100, a once-daily eye drop for presbyopia, a condition that reduces near vision with age. It is advancing the therapy through Phase 3 trials and positioning for potential regulatory submission. Investors track the stock for its lead asset's commercial optionality in the vision care market.
52W Range: $3.06-$32.92
Congressional Interest in LENZ Therapeutics, Inc. (LENZ)
No congressional trades have been disclosed for LENZ Therapeutics, Inc. (LENZ) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading LENZ?
No congressional trades found for this stock.